Top Tweets for #ASH20SL
Important phase 2 data on Isatuximab single agent in relapsed AL #amyloidosis presented by Terri Parker @vsanchorawala @SWOG. Very well tolerated and ORR 77%👍
Would it work after Dara relapse?🤔#ASH20SL @AmyloidosisSupp @CAMPamyloidosis @Amyloidosisfdn
SWOG S 1702 Isatuximab for relapsed AL Amyloidosis @ASH_hematology #ASH20:
- 36 patients
- Most got previous PI (90%)
- 67% carload involvement #mmsm
RAS mutations as a potential new target in #myeloma. 👏Dr @shirongli from our lab presented his work (#2275) at #ASH20 on GCK = MAP4K2 inhibition to treat RAS mutated myeloma @columbiacancer #ASH20 #ASH20SL
Great presentation by 👏Dr Jing Fu from our lab showing that Checkpoint Inhibitor PD-1H/VISTA mediates MMP-13 induced osteoclast activation and #myeloma Bone Disease➡️connecting MM bone disease and immunosuppression
@columbiacancer #ASH20 #ASH20SL #mmsm
Congratulations @jasonvalent1 and @khouri_jack for👏outstanding presentation on CAEL-101 (11-1F4mAb)🙏🙏for moving CAEL-101 to the next level during #COVID19 pandemic!! Great data on renal response! Need GLS as a marker for cardiac response @CaelumBio @CamilleVEdwards #ASH20SL
#724 Niels Van De Donk showed Phase 1 data: IBER (CC-220)/ DEX/ DARA or BORT in RRMM➡️ORR 42% Iber/Dex/Dara and 61% IBER/DEX/BOR in RRMM
@BMS_Myeloma_US Do we need to treat patients with Len and Pom before using IBER?? Time to allow most potent drugs upfront #ASH20 #ASH20SL
My favorite topic #amyloidosis: Update on Andromeda Dara-CyBorD vs CyBorD by Ray Comenzo
➡️Dara-CyBorD results in longer PFS
➡️Dara-CyBorD significantly delays organ deterioration
Dara-CyBorD is clearly the new SOC in AL! But is Dara maintenance also the new SOC? #ASH20 #ASH20SL
Proud of @columbiacancer and @BMT_updates = Markus Mapara being part of this breakthrough approach for #sicklecelldisease #ASH20 #ASH20SL
Exciting advances today in genome editing towards a cure for both sickle-cell disease and β-thalassemia @NEJM #ASH20 @ASH_hematology #CRISPR
https://t.co/LFU2gzaecl
Congratulations @rajshekharucms 👏👏for outstanding research and presentation on developing a model for VTE-risk factors in #myeloma. I am sure that your PRISM VTE risk assessment model will find wide application #ASH20 #ASH20SL #mmsm
CONGRESS | #ASH20 | @rajshekharucms presented a retrospective cohort study to identify VTE-related risk factors in patients with #myeloma treated at @ClevelandClinic. With these results, they developed the PRISM risk assessment model and validated it internally 📈 #mmsm
Phase1 ANCHOR trial presented by @OcioEnrique Melflufen/dex + Dara or bortezemib showed ORR 73% (Dara) and 62%(Bor). Grade 3/4 thrombocytopenia 73% and neutropenia 67%➡️reminds me of bendamustine-tox #ASH20 #ASH20SL #mmsm
DCdP vs Dcd with Pom added in case of PD presented by 👏@MichaelSebag on behalf of @ResearchMyeloma. Quadruplets achieve high OR 88.6% in RRMM, Pom can be added at time of PD as the PSF shows NS difference. I favour the quadruplets from the start #ASH20 #ASH20SL #mmsm
AMG701 (BCMAxCD3) BITE presented by Simon Harrison results in 83% ORR in the most recent evaluable cohort. 6 patients achieved durable responses up to 22 mos and MRD- was observed. So many BITEs... who will be the winner? @AmgenOncology #ASH20 #ASH20SL #mmsm
Great presentation by @AlGarfall on the SC BITE Teclistamab (BCMAxCD3) with 73% VGPR/CR and good AE profile !! @JanssenUS #ASH20SL #mmsm
58.5% photophobia seems to be a significant AE and one of the main reason for discontinuation. ?? for @myelomaMD : did all photophobias reverse to baseline?
#ASH20SL #mmsm
Congress| #ASH20| @DMadduri, @IcahnMountSinai, presented results of the CARTITUDE-1 study of ciltacabtagene autoleucel in relapsed/refractory MM, showing an ORR of 96.9% and sCR of 67% with median DOR not yet reached with a median follow-up of 8.8 months. #mmsm
Last Seen Hashtags on Sotwe
momson((((***)))) +filter:videos
Seen from Turkey
ruinedorgasm #cumcontrol
Seen from United Kingdom
rectal
仙台ときめきMap
Seen from United States
momson()() +filter:native_video
nolimit()**************+filter:native_video
NaoJinguji
Seen from Malaysia
blazingsaddle
Seen from United Kingdom
萧熏儿
Seen from United States
sizetwitter
Seen from United Kingdom
Most Popular Users
Elon Musk 
@elonmusk
241.1M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
112.5M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.2M followers
NASA
@nasa
92.2M followers
Justin Bieber
@justinbieber
91.4M followers
KATY PERRY
@katyperry
88.8M followers
Taylor Swift
@taylorswift13
82.7M followers
Lady Gaga
@ladygaga
74.2M followers
Virat Kohli
@imvkohli
71.6M followers
Kim Kardashian
@kimkardashian
70.3M followers
YouTube
@youtube
68.7M followers
Neymar Jr
@neymarjr
64.5M followers
Bill Gates
@billgates
64.5M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
61.9M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers